Companies / Switzerland
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Lonza Buys Cambrex's Biopharmaceutical Units
October 2006 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
To exploit the booming biopharmaceutical sector, Swiss contract manufacturing organisation (CMO) Lonza has agreed to purchase two businesses from US firm Cambrex. Lonza is paying US$460mn for its Research Bioproducts division and its Microbial Biopharmaceuticals business. The transaction further increases Lonza's transition into a life science company, which it first announced two years ago, and the deal reduces the Basel-based group's reliance on the highly competitive production of traditional pharmaceuticals for